ATAI Life Sciences NV (ATAI)
1.17
-0.02
(-1.68%)
USD |
NASDAQ |
Sep 27, 16:00
1.175
0.00 (0.00%)
After-Hours: 20:00
ATAI Life Sciences Cash from Financing (Quarterly): 0.326M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.326M |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -8.461M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -0.10M |
| March 31, 2023 | 0.206M |
| December 31, 2022 | -0.922M |
| September 30, 2022 | 19.78M |
| June 30, 2022 | 1.794M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.132M |
| December 31, 2021 | 1.723M |
| September 30, 2021 | 3.877M |
| June 30, 2021 | 373.76M |
| March 31, 2021 | 30.50M |
| December 31, 2020 | 81.98M |
| September 30, 2020 | 18.06M |
| June 30, 2020 | 3.204M |
| March 31, 2020 | 9.807M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-8.461M
Minimum
Dec 2023
373.76M
Maximum
Jun 2021
29.76M
Average
1.758M
Median
Cash from Financing (Quarterly) Benchmarks
| Affimed NV | 1.329M |
| InflaRx NV | -0.1148M |
| BioNTech SE | -24.58M |
| Immatics NV | -2.259M |
| CureVac NV | -1.299M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.23M |
| Cash from Investing (Quarterly) | 16.30M |
| Free Cash Flow | -79.22M |
| Free Cash Flow Per Share (Quarterly) | -0.1012 |
| Free Cash Flow to Equity (Quarterly) | -15.13M |
| Free Cash Flow to Firm (Quarterly) | -15.64M |
| Free Cash Flow Yield | -40.74% |